Results 211 to 220 of about 756,250 (282)

Emerging Strategies for Cardio-Renal Protection Beyond RAAS Blockade: <i>Emphasis on Non-diabetic CKD and Resistant Hypertension</i>. [PDF]

Saudi Med J
Alrashidi FS.
europepmc   +1 more source

Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11320-11327, December 2026.
ABSTRACT Aims While the new kidney protective therapies have transformed chronic kidney disease (CKD) management in patients with Type 2 diabetes mellitus (T2DM), treatment options for CKD in Type 1 diabetes mellitus (T1DM) have remained unchanged for 30 years, limited to renin–angiotensin system inhibitors (RASis).
Frances Perry, Silvia J. Leon, Kate Polecina, Ruth Getachew, Nicole Askin, Thomas Ferguson, Reid Whitlock, Zihe Zheng, Carolina Aldworth, Arvind Katta, Jacob Earl, Mauricio Beller Ferri, Navdeep Tangri   +12 more
wiley   +1 more source

Combination pharmacotherapy in type 2 diabetes and chronic kidney disease: translating evidence into clinical practice. [PDF]

Nephrol Dial Transplant
Lovshin JA.
europepmc   +1 more source

Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11702-11709, December 2026.
ABSTRACT Aims Real‐world long‐term data on oral semaglutide are limited. We evaluated its 24‐month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D). Materials and Methods This retrospective real‐world study included 232 adults with T2D initiating oral semaglutide at an Italian diabetes clinic.
Maria Pompea Antonia Baldassarre, Giulia Di Dalmazi, Federica Carrieri, Giorgia Centorame, Luigi Piacentino, Sara Coluzzi, Gloria Formoso   +6 more
wiley   +1 more source

Redefining Therapeutic Targets in Hypertension and Cardiometabolic Syndrome. [PDF]

Circ Res
Masenga SK, Kirabo A.
europepmc   +1 more source

Nephroprotective Effects of the Dual GCGR/GLP‐1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11915-11926, December 2026.
ABSTRACT Aims Survodutide is a novel long‐acting dual glucagon (GCGR)/glucagon‐like peptide‐1 (GLP‐1R) receptor agonist currently in phase‐3 clinical development for the treatment of people living with obesity and metabolic dysfunction‐associated steatohepatitis.
Alexander Hamilton, Louise Thisted, Maria Ougaard, Max Hahn, Kasper Andersen, Johanna Perens, Robert Augustin, Besnik Bajrami, Wolfgang Rist, Michael Christensen, Henrik H. Hansen, Thomas Klein   +11 more
wiley   +1 more source

Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine

Histopathology, Volume 89, Issue 6, Page 1011-1019, December 2026.
CYP11B2 immunohistochemistry identifies aldosterone‐producing nodules and enables objective subtyping using the B2 ratio (B2R), defined as the size ratio between the largest and second‐largest CYP11B2‐positive nodules. A B2R ≥8.1 indicates classical histology with a dominant lesion and high likelihood of cure, whereas B2R <8.1 reflects non‐classical ...
Adam Stenman, Tim Nilsson, Henrik Falhammar, C. Christofer Juhlin   +3 more
wiley   +1 more source

Severe ADEM‐Like Neuroinflammatory Disease and Cerebrovascular Fragility With Recurrent Pseudoaneurysms and Moyamoya in a Familial Germline CBL Mutation: Expanding the Clinical Phenotype

American Journal of Medical Genetics Part A, Volume 200, Issue 11, Page 2568-2574, November 2026.
ABSTRACT Heterozygous germline variants in CBL disrupt its function as a negative regulator of the Ras/MAPK pathway, classically predisposing to Juvenile myelomonocytic leukemia (JMML) and moyamoya. We describe two affected siblings carrying a paternally inherited CBL variant (c.1210 T> C, p.
Michal Bar‐Hakim, Anat Abramovich, Sara Via‐Dorembus, Gali Heimer, Bruria Ben‐Zeev, Etai Adam, Assaf A. Barg, Jonathan Roth, Basheer Sheick‐Yousif, Rony Beeri Berkowiz, Michal Feldon, Haim Bassan, Moran Hausman‐Kedem   +12 more
wiley   +1 more source

Renin-Angiotensin Signaling and Vascular Function: Insights into Health and Disease. [PDF]

Acta Physiol (Oxf)
Bertoldi G, Sonkusare SK.
europepmc   +1 more source

Pharmacokinetics, mass balance, and metabolism of [¹⁴C]SPH3127 (sitokiren), a novel direct renin inhibitor in humans. [PDF]

Front Pharmacol
Ma S, Huang X, Yan S, Liu H, Zhang H, Zhang Y, Cui W, Ding C, Diao X, Miao L.   +9 more
europepmc   +1 more source